Twinbeech Capital LP Fate Therapeutics Inc Transaction History

Twinbeech Capital LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $629,846 - $1.52 Million	63,879 Added 29.97%	277,047 $2.8 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $4.49 Million - $7.69 Million	213,168 New	213,168 $4.78 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $958,288 - $2.28 Million	-53,897 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $1.6 Million - $3.25 Million	53,897 New	53,897 $2.09 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $1.65 Million - $2.22 Million	-34,427 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $1.18 Million - $1.9 Million	19,861 Added 136.35%	34,427 $2.04 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $475,188 - $653,746	7,066 Added 94.21%	14,566 $1.26 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $541,200 - $880,500	7,500 New	7,500 $618,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.